volitionrx ltd - VNRX
VNRX
Close Chg Chg %
0.24 0.01 4.58%
Closed Market
0.25
+0.01 (4.58%)
Volume: 1.49M
Last Updated:
Dec 30, 2025, 3:59 PM EDT
Company Overview: volitionrx ltd - VNRX
VNRX Key Data
| Open $0.23 | Day Range 0.23 - 0.26 |
| 52 Week Range 0.22 - 0.94 | Market Cap $29.47M |
| Shares Outstanding 122.80M | Public Float 97.40M |
| Beta 1.26 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.23 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.12M |
VNRX Performance
| 1 Week | 0.32% | ||
| 1 Month | -22.04% | ||
| 3 Months | -61.30% | ||
| 1 Year | -58.20% | ||
| 5 Years | -93.55% |
VNRX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
5
Full Ratings ➔
About volitionrx ltd - VNRX
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
VNRX At a Glance
VolitionRX Ltd.
1489 West Warm Springs Road
Henderson, Nevada 89014
| Phone | 1-646-650-1351 | Revenue | 1.23M | |
| Industry | Medical Specialties | Net Income | -26,967,836.00 | |
| Sector | Health Technology | 2024 Sales Growth | 59.101% | |
| Fiscal Year-end | 12 / 2025 | Employees | 85 | |
| View SEC Filings |
VNRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 42.09 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.071 |
| Enterprise Value to Sales | 43.19 |
| Total Debt to Enterprise Value | 0.109 |
VNRX Efficiency
| Revenue/Employee | 14,511.894 |
| Income Per Employee | -317,268.659 |
| Receivables Turnover | 11.156 |
| Total Asset Turnover | 0.066 |
VNRX Liquidity
| Current Ratio | 0.521 |
| Quick Ratio | 0.521 |
| Cash Ratio | 0.419 |
VNRX Profitability
| Gross Margin | -5.571 |
| Operating Margin | -2,190.898 |
| Pretax Margin | -2,209.789 |
| Net Margin | -2,186.266 |
| Return on Assets | -144.406 |
| Return on Equity | N/A |
| Return on Total Capital | 141.289 |
| Return on Invested Capital | N/A |
VNRX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -30.495 |
| Total Debt to Total Assets | 61.924 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -24.581 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Volitionrx Ltd - VNRX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 90.04K | 306.39K | 775.30K | 1.23M | |
Sales Growth
| +570.25% | +240.30% | +153.04% | +59.10% | |
Cost of Goods Sold (COGS) incl D&A
| - | 1.19M | 1.41M | 1.30M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.15M | 1.19M | 1.41M | 1.30M | |
Depreciation
| 1.05M | 1.11M | 1.33M | 1.30M | |
Amortization of Intangibles
| - | 91.65K | 75.56K | 84.91K | |
COGS Growth
| - | - | +18.78% | -7.75% | - |
Gross Income
| - | (882.03K) | (636.33K) | (68.72K) | |
Gross Income Growth
| - | - | +27.86% | +89.20% | - |
Gross Profit Margin
| - | -287.88% | -82.07% | -5.57% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 27.28M | 30.90M | 35.35M | 26.96M | |
Research & Development
| 14.57M | 13.73M | 18.43M | 13.32M | |
Other SG&A
| 12.71M | 17.17M | 16.92M | 13.64M | |
SGA Growth
| +34.91% | +13.27% | +14.41% | -23.75% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | (240.31K) | (28.76K) | - |
EBIT after Unusual Expense
| (28.33M) | (31.78M) | (35.75M) | (27.00M) | |
Non Operating Income/Expense
| 1.50M | 1.35M | 291.94K | 78.59K | |
Non-Operating Interest Income
| 2.73K | 125.27K | 93.32K | 9.95K | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 155.80K | 173.09K | 221.62K | 340.36K | |
Interest Expense Growth
| +20.03% | +11.09% | +28.04% | +53.58% | |
Gross Interest Expense
| 155.80K | 173.09K | 221.62K | 340.36K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (26.99M) | (30.60M) | (35.68M) | (27.26M) | |
Pretax Income Growth
| -32.31% | -13.37% | -16.60% | +23.60% | |
Pretax Margin
| -29,976.99% | -9,986.71% | -4,601.70% | -2,209.79% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (26.99M) | (30.60M) | (35.68M) | (27.26M) | |
Minority Interest Expense
| (175.12K) | (329.68K) | (358.00K) | (290.15K) | |
Net Income
| (26.81M) | (30.27M) | (35.32M) | (26.97M) | |
Net Income Growth
| -31.75% | -12.88% | -16.68% | +23.65% | |
Net Margin Growth
| -29,782.49% | -9,879.11% | -4,555.53% | -2,186.27% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (26.81M) | (30.27M) | (35.32M) | (26.97M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (26.81M) | (30.27M) | (35.32M) | (26.97M) | |
EPS (Basic)
| -0.5092 | -0.5469 | -0.4958 | -0.3116 | |
EPS (Basic) Growth
| -13.28% | -7.40% | +9.34% | +37.15% | |
Basic Shares Outstanding
| 52.66M | 55.35M | 71.23M | 86.53M | |
EPS (Diluted)
| -0.5092 | -0.5469 | -0.4958 | -0.3116 | |
EPS (Diluted) Growth
| -13.28% | -7.40% | +9.34% | +37.15% | |
Diluted Shares Outstanding
| 52.66M | 55.35M | 71.23M | 86.53M | |
EBITDA
| (27.19M) | (30.59M) | (34.58M) | (25.72M) | |
EBITDA Growth
| -34.55% | -12.52% | -13.02% | +25.61% | |
EBITDA Margin
| -30,197.06% | -9,984.48% | -4,459.69% | -2,085.33% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 2.575 | |
| Number of Ratings | 5 | Current Quarters Estimate | -0.04 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.114 | |
| Last Quarter’s Earnings | -0.04 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.212 | Next Fiscal Year Estimate | 0.063 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 4 | 4 | 5 | 4 |
| Mean Estimate | -0.04 | -0.04 | -0.11 | 0.06 |
| High Estimates | -0.04 | -0.04 | 0.05 | 0.54 |
| Low Estimate | -0.04 | -0.05 | -0.17 | -0.17 |
| Coefficient of Variance | 0.00 | -11.76 | -81.02 | 518.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 3 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Overweight |
SEC Filings for Volitionrx Ltd - VNRX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Volitionrx Ltd - VNRX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 18, 2025 | Cameron John Reynolds President and CEO; Director | 2,554,847 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.35 per share | 894,196.45 |
| Oct 1, 2025 | Jacob Vincent Micallef Chief Scientific Officer | 398,939 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 239,363.40 |
| Oct 1, 2025 | Salvatore Thomas Butera CEO - Volition Veterinary | 332,285 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 199,371.00 |
| Oct 1, 2025 | Rodney Gerard Rootsaert Secretary | 145,075 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 87,045.00 |
| Oct 1, 2025 | Louise Batchelor Group Chief Marketing Officer | 154,282 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 92,569.20 |
| Oct 1, 2025 | Michel Gaetan Chief Operating Officer | 369,079 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 221,447.40 |
| Oct 1, 2025 | Gael Forterre Chief Commercial Officer | 160,924 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $0.6 per share | 96,554.40 |
| Mar 28, 2025 | Guy Archibald Innes Director | 868,689 | Open market or private purchase of non-derivative security Non-derivative transaction at $0.55 per share | 477,778.95 |